CDTTW
Conduit Pharmaceuticals Inc.Key Statistics
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. (CDTTW) is a cutting-edge biopharmaceutical firm committed to creating revolutionary therapies for oncology and autoimmune diseases, targeting significant unmet medical needs in these essential sectors. Leveraging proprietary drug delivery technologies, the company is translating advanced scientific research into clinical solutions aimed at improving patient outcomes. With a strong pipeline and strategic collaborations, Conduit Pharmaceuticals is poised for growth, making it an appealing investment choice in the dynamic biotechnology landscape as it progresses through critical phases of clinical development.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.83M |
| Operating Margin | 0.00% |
| Return on Equity | -69.70% |
| Return on Assets | -23.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $163.36 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 343,920 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDTTW and any ticker you trade — then tracks every position and per-strategy win rate.